Search results for "Visual Acuity"

showing 10 items of 456 documents

TREATMENT OF PERSISTENTLY OPEN MACULAR HOLES WITH HEAVY SILICONE OIL (DENSIRON 68) VERSUS C2F6. A PROSPECTIVE RANDOMIZED STUDY

2016

Abstract PURPOSE: To compare the efficacy of a mixture of silicone oil and perfluorohexyloctane (Densiron 68) with C2F6 gas endotamponade in the retreatment of persistently open full-thickness macular holes. METHODS: In this prospective randomized study, 21 consecutive patients who were unsuccessfully operated on for large idiopathic full-thickness macular hole were randomly assigned to undergo a second vitrectomy with 20% perfluoroethane gas (C2F6, Group A) or with Densiron 68 tamponade (Group B). PRIMARY OUTCOMES: Endpoint (12 months) full-thickness macular hole closure rate by spectral domain optical coherence tomography and logMAR corrected distance visual acuity. SECONDARY OUTCOMES: po…

MaleReoperationmedicine.medical_specialtyVisual acuitygenetic structuresmedicine.medical_treatmentVisual AcuityVitrectomyEndotamponadelaw.invention03 medical and health scienceschemistry.chemical_compound0302 clinical medicineRandomized controlled triallawVitrectomymedicineHumansSilicone OilsMacular hole Densiron Silicone oilProspective randomized studyProspective StudiesEndotamponadeHeavy silicone oilProspective cohort studyAgedAged 80 and overFluorocarbonsSettore MED/30 - Malattie Apparato Visivobusiness.industryGeneral MedicineMiddle AgedRetinal PerforationsSilicone oilSurgeryOphthalmologychemistry030221 ophthalmology & optometryFemalemedicine.symptombusinessTomography Optical Coherence030217 neurology & neurosurgeryRetina
researchProduct

A two-year follow-up of oral antioxidant supplementation in primary open-angle glaucoma: an open-label, randomized, controlled trial

2014

Purpose To evaluate the effect of oral antioxidant supplementation (OAS) on primary open-angle glaucoma (POAG) over a 2-year follow-up period. Patients and methods In this open-label, randomized controlled trial, 117 eyes of 117 patients with mild or moderate POAG and intraocular pressure under control with topical antiglaucoma medications were recruited and randomly divided into three groups according to supplementation: (1) OAS with (ICAPS R® – Alcon Laboratories, n = 26); (2) OAS without ω-3 fatty acids (OFTAN MACULA® – Laboratorios Esteve, n = 28); and (3) a control group without OAS (n = 63). They all underwent visual field (VF) tests (Humphrey 24-2) and scans using a Fourier-domain op…

MaleRetinal Ganglion CellsIntraocular pressuremedicine.medical_specialtygenetic structuresOpen angle glaucomaVisual AcuityAdministration OralGlaucomaAntioxidantslaw.inventionchemistry.chemical_compoundNerve FibersRandomized controlled triallawOphthalmologyFatty Acids Omega-3medicineHumansProspective StudiesAntihypertensive AgentsIntraocular PressureAgedbusiness.industryRetinalGeneral MedicineMiddle Agedmedicine.diseaseeye diseasesVisual fieldAbsolute deviationOphthalmologychemistryDietary SupplementsVisual Field TestsFemalesense organsVisual FieldsOpen labelbusinessGlaucoma Open-AngleTomography Optical CoherenceFollow-Up StudiesActa Ophthalmologica
researchProduct

Optical coherence tomography angiography evaluation of peripapillary microvascular changes after rhegmatogenous retinal detachment repair

2021

PURPOSE To evaluate the radial peripapillary capillary plexus (RPCP) vessel density (VD) and the retinal nerve fiber layer (RNFL) thickness in eyes successfully treated with pars plana vitrectomy for primary rhegmatogenous retinal detachment. METHODS In this cross-sectional multicenter clinical study, eyes with a minimum 12-month follow-up were reexamined. The RPCP VD and RNFL thickness in the rhegmatogenous retinal detachment subfields of the affected eye (study group) were compared with the corresponding areas of the healthy fellow eyes (control group). RESULTS Fifty-three eyes were included in the study. A significantly lower RPCP VD and RNFL thickness were observed in those subfields af…

MaleRetinal Ganglion Cellsgenetic structuresComputed Tomography Angiographymedicine.medical_treatmentNerve fiber layerVisual AcuityVitrectomyEyeradial peripapillary capillary plexuschemistry.chemical_compoundNerve FibersVitrectomyTomographyRetinal detachment repairRetinal detachmentGeneral MedicineMiddle AgedAxial Length Eyemedicine.anatomical_structureFemaleTomography Optical CoherencePars planamedicine.medical_specialtyBiometryOptic DiskEndotamponaderetinal detachmentOCT-angiography; Radial peripapillary capillary plexus; Retinal detachment; Retinal nerve fiber layer; Aged; Axial Length Eye; Biometry; Cross-Sectional Studies; Endotamponade; Female; Humans; Male; Middle Aged; Nerve Fibers; Optic Disk; Retinal Detachment; Retinal Ganglion Cells; Retinal Vessels; Retrospective Studies; Visual Acuity; Computed Tomography Angiography; Tomography Optical Coherence; VitrectomyOphthalmologymedicineHumansAxial LengthAgedRetrospective StudiesRetinabusiness.industryradial peripapillary capillary plexus; OCT-angiography; retinal nerve fiber layer; retinal detachmentRetinal Vesselsretinal nerve fiber layerRetinalOptical coherence tomography angiographymedicine.diseaseeye diseasesOphthalmologyCross-Sectional StudieschemistryOptical Coherencesense organsOCT-angiographybusiness
researchProduct

Effect of multizone refractive multifocal contact lenses on the Cirrus HD OCT retinal measurements

2011

Background Simultaneous vision multifocal contact lenses are widely used to alleviate the symptoms of presbyopia. These contact lenses create simultaneous retinal images due to the incoming light distribution being divided into two or more focuses. Our aim was to evaluate whether the multizone refractive multifocal contact lenses affect the measurements of the retinal nerve fibre layer (RNFL) and macular thickness using optical coherence tomography (OCT). Methods In this cross-over study, 30 eyes of 30 subjects with a mean age of 50.42 ± 7.82 years were fitted with multizone refractive multifocal contact lenses. Using the RNFL Thickness Analysis mode of the Cirrus HD (Carl Zeiss, Meditec, D…

MaleRetinal Ganglion Cellsmedicine.medical_specialtyMaterials sciencegenetic structuresContact LensesVisual AcuityRefraction Ocularchemistry.chemical_compoundNerve FibersOpticsOptical coherence tomographySignal strengthOphthalmologymedicineHumansÓpticaCross-Over Studiesmedicine.diagnostic_testbusiness.industryRetinalEquipment DesignPresbyopiaPresbyopiaMiddle Agedmedicine.diseaseRefractioneye diseasesContact lensOphthalmologychemistryOftalmologíaFemaleCirrussense organsTomographybusinessTomography Optical CoherenceOptometryClinical and Experimental Optometry
researchProduct

Retrograde Maculopathy in Patients With Glaucoma

2017

PURPOSE Macular optical coherence tomography (OCT) analysis can be used for quantitative measures of optic nerve atrophy at a location far from the optic nerve head. This recently led to the finding of microcystic macular edema (MME), that is vacuolar inclusions in the macular inner nuclear layer, in some glaucoma patients. The involvement of individual retinal layers is yet unclear in glaucoma. In this study we systematically investigated glaucoma-induced changes in macular layers to evaluate whether glaucoma-associated damage extends beyond the macular ganglion cell layer. PATIENTS AND METHODS We included 218 consecutive patients and 282 eyes with confirmed primary open-angle glaucoma or …

MaleRetinal Ganglion Cellsmedicine.medical_specialtygenetic structuresOptic DiskVisual AcuityNerve fiber layerGlaucoma610 Medicine & healthExfoliation SyndromeMacular EdemaRetina03 medical and health sciencesNerve Fibers0302 clinical medicineOphthalmologymedicineHumans610 Medicine & healthMacular edemaGanglion cell layerIntraocular PressureAgedRetrospective StudiesAged 80 and overRetinabusiness.industryMiddle Agedmedicine.diseaseeye diseasesOphthalmologyCross-Sectional Studiesmedicine.anatomical_structureInner nuclear layer030221 ophthalmology & optometryOptic nerveVisual Field TestsMaculopathyFemalesense organsbusinessGlaucoma Open-AngleTomography Optical Coherence030217 neurology & neurosurgeryJournal of Glaucoma
researchProduct

Heavy versus standard silicone oil in the management of retinal detachment with macular hole in myopic eyes

2011

PURPOSE: The purpose of this study was to compare pars plana vitrectomy (PPV) with 1000 cSt silicone oil endotamponade and PPV with densiron endotamponade for retinal detachment with macular hole and posterior staphyloma in highly myopic eyes. PATIENTS AND METHODS: In a prospective study, 30 eyes of 30 patients were randomly assigned to PPV and densiron (n = 15) or PPV with silicone oil (n = 15). All eyes had laser photocoagulation of the macular hole rim after PPV. Silicone oil or densiron was removed 12 weeks after surgery. Patients were followed-up for 6 months after oil removal. RESULTS: In the densiron group, the retinal reattachment rate was 100% with densiron in situ and 87% after it…

MaleTime FactorsVisual acuityIntraoperative Complicationgenetic structuresmedicine.medical_treatmentVisual AcuityRetinal perforationVitrectomyPostoperative ComplicationsVitrectomySilicone OilsProspective StudiesEndotamponadeIntraoperative ComplicationsMacular holeLaser Coagulationhigh myopic eyeRetinal detachmentGeneral MedicineMiddle AgedTreatment Outcomemedicine.anatomical_structureMyopia Degenerativemacular hole retinal detachmentDrainageFemalemedicine.symptomLaser coagulationDilatation PathologicHumanAdultPars planamedicine.medical_specialtyTime Factorsilicone oilOphthalmologymedicineHumansAgeddensironbusiness.industryRetinal DetachmentRetinal Perforationsmedicine.diseaseeye diseasesProspective StudieOphthalmologyRetinal PerforationPostoperative Complicationsense organsbusiness
researchProduct

Intravitreal dexamethasone implant one month before versus concomitant with cataract surgery in patients with diabetic macular oedema: the dexcat stu…

2020

Purpose: To report clinical outcomes of two different timings of intravitreal dexamethasone (DEX) implant administration for prevention of diabetic macular oedema (DME) worsening following cataract surgery. Methods: This multicentre, retrospective study included patients with DME who received an intravitreal DEX implant 1 month before cataract surgery, ‘precataract DEX’ group, or at the time of cataract surgery, ‘concomitant treatments’ group. Inclusion criteria were a follow-up ≥3 months and ophthalmological examination with optical coherence tomography (OCT) imaging at baseline (cataract surgery) and throughout follow-up. Anatomical improvement was considered to be a decrease in OCT centr…

MaleTime FactorsVisual acuitygenetic structuresmedicine.medical_treatmentVisual AcuityDexamethasone0302 clinical medicinedexamethasone implantDrug Implantsdiabetescataract surgeryGeneral MedicineTreatment Outcomediabetic macular oedemaIntravitreal InjectionsFemalecataract surgery; dexamethasone implant; diabetes; diabetic macular oedemamedicine.symptomTomography Optical Coherencemedicine.drugmedicine.medical_specialtyCataract ExtractionCataractMacular Edema03 medical and health sciencesOphthalmologyDiabetes mellitusmedicineHumansAdverse effectGlucocorticoidsDexamethasoneAgedRetrospective StudiesDiabetic RetinopathySettore MED/30 - Malattie Apparato Visivobusiness.industryRetrospective cohort studyCataract surgerymedicine.diseaseeye diseasesOphthalmologydiabeteConcomitant030221 ophthalmology & optometryImplantbusiness030217 neurology & neurosurgeryFollow-Up StudiesActa Ophthalmologica
researchProduct

Outcomes of cataract surgery in diabetic patients: results of the Pan American Collaborative Retina Study Group.

2014

Purpose: This study was designed to evaluate the visual and anatomical outcomes after cataract surgery in diabetic patients with different intraoperative therapeutic strategies. Methods: The research design comprised of a multicentric, retrospective, interventional study conducted at 6 centers in Argentina, Brazil, Costa Rica, Puerto Rico, Spain, and Venezuela. We included 138 diabetic patients with at least 6-month follow-up following phacoemulsification and intraocular lens implantation. Best-corrected visual acuity (BCVA) and central subfield thickness were collected at baseline and at 1-, 2-, 3-, and 6-month follow-up. Of these, 42 cases were not treated with any intraoperative coadjuva…

MaleVascular Endothelial Growth Factor ATriamcinolone acetonideVisual acuitygenetic structuresmedicine.medical_treatmentExtração de catarataVisual AcuityIntraocular lensCuidados intraoperatóriosAngiogenesis InhibitorsTriamcinolonelcsh:OphthalmologyLens Implantation IntraocularDiabetic retinopathyAntibodies monoclonalAged 80 and overGeneral MedicineDiabetic retinopathyMiddle AgedMulticenter studyBevacizumabTreatment OutcomeCataract extractionChemotherapy AdjuvantEstudo multicêntricoIntravitreal InjectionsFemalemedicine.symptommedicine.drugAdultmedicine.medical_specialtyBevacizumabAntibodies Monoclonal HumanizedCataractMacular EdemaIntraoperative careOphthalmologyEdema macularmedicineAnticorpos monoclonaisHumansMacular edemaGlucocorticoidsAgedRetrospective StudiesMacular edemaDiabetic RetinopathyIntraoperative CarePhacoemulsificationbusiness.industryRetinopatia diabéticaPhacoemulsificationCataract surgeryFacoemulsificaçãomedicine.diseaseSurgeryImplante de lente intraocularOphthalmologyLens implantation intraocularlcsh:RE1-994businessFollow-Up StudiesArquivos brasileiros de oftalmologia
researchProduct

A randomized trial of intravitreal bevacizumab vs. ranibizumab for myopic CNV.

2014

AIMS: The aim was to compare the efficacy of intravitreal therapy with bevacizumab and ranibizumab for choroidal neovascularization (CNV) in pathologic myopia (PM). METHODS: This was a prospective multicenter randomized nonblinded trial. RESULTS: In seven centers, 78 eyes were randomized 1:1 to treatment with bevacizumab (group B, 40 eyes) or ranibizumab (group R, 38 eyes) given with an "on demand" regimen (PRN). The mean follow-up was 19 months (SD 2, range 12-24). The mean BCVA at baseline was 0.60 logMAR (20/80 Snellen equivalent, Seq) and 50 letter score (ls). Mean final BCVA was 0.51 LogMAR (20/63 Seq) and 57 ls (p = 0.0009 and p = 0.0002, respectively). In group B, mean basal BCVA was…

MaleVascular Endothelial Growth Factor AVisual Acuity/drug effectsVisual acuitygenetic structuresVisual AcuityAngiogenesis Inhibitorslaw.inventionBevacizumab/therapeutic use0302 clinical medicineRandomized controlled triallawMyopiaMedicineProspective StudiesProspective cohort studyPathological myopiaAged 80 and overMiddle AgedSensory SystemsBevacizumabVascular endothelial growth factor AChoroidal neovascularizationIntravitreal InjectionsMyopia DegenerativeFemalemedicine.symptommedicine.drugAdultmedicine.medical_specialtyBevacizumabNeuroscience(all)CNVBevacizumab; CNV; Pathological myopia; Ranibizumab.Antibodies Monoclonal HumanizedRanibizumab/therapeutic use03 medical and health sciencesCellular and Molecular NeuroscienceOphthalmologyRanibizumabVascular Endothelial Growth Factor A/antagonists & inhibitorsHumansAngiogenesis Inhibitors/therapeutic useIntravitreal bevacizumabAgedpathological myopia CNV bevacizumab ranibizumabSettore MED/30 - Malattie Apparato Visivobusiness.industryTherapeutic effectChoroidal Neovascularization/drug therapyeye diseasesChoroidal NeovascularizationOphthalmologyRegimen030221 ophthalmology & optometryMyopia Degenerative/drug therapysense organsRanibizumabbusiness030217 neurology & neurosurgeryFollow-Up StudiesGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie
researchProduct

Outcomes of treatment of pediatric choroidal neovascularization with intravitreal antiangiogenic agents: the results of the KKESH International Colla…

2014

Purpose: To evaluate safety and clinical results of intravitreal antiangiogenic agents for choroidal neovascularization in pediatric patients. Methods: Retrospective, multicenter, interventional case series. A total of 45 eyes of 39 pediatric patients with choroidal neovascularization of various etiologies were treated with intravitreal injection of antiangiogenic agents (1.25 mg per 0.05 mL of bevacizumab or 0.5 mg per 0.05 mL of ranibizumab). Results: There were 24 girls and 15 boys with group median age of 13 years (range, 3–17 years). Mean follow-up period was 12.8 months (range, 3–60 months). Median visual acuity in terms of logarithm of the minimum angle of resolution at presentation …

MaleVascular Endothelial Growth Factor Amedicine.medical_specialtyVisual acuitygenetic structuresBevacizumabAdolescentVisual AcuityAngiogenesis InhibitorsAntibodies Monoclonal HumanizedOphthalmologyRanibizumabmedicineHumansChildRetrospective StudiesRetinabusiness.industryRetrospective cohort studyGeneral Medicineeye diseasesChoroidal NeovascularizationClinical trialBevacizumabOphthalmologyChoroidal neovascularizationmedicine.anatomical_structureTreatment OutcomeChild PreschoolIntravitreal InjectionsEtiologyFemalesense organsmedicine.symptomRanibizumabbusinessTomography Optical Coherencemedicine.drugFollow-Up StudiesRetina (Philadelphia, Pa.)
researchProduct